I received my PhD with Cum Laude from the Netherlands Cancer Institute, defining a novel mode of action of a broadly used anti-cancer drug, doxorubicin, and its anthracycline members. I discovered that doxorubicin and other anthracycline members can also destabilize nucleosomes and evict histones from particular chromatin regions upon intercalating into the chromatin. As a result, the DNA damage response is attenuated and the epigenome of the cell is deregulated. After a brief period of post-doc training at the Netherlands Cancer Institute, I moved to the Department of Genetics, Stanford University in the US, where I developed unique genome-wide screen systems to study the function of the non-coding genome. In 2018 I started my research group at the Department of Cell and Chemical Biology. I was awarded the Antoni van Leeuwenhoek Prize from NKI-AvL, the Academic Excellence Award from China, the Gisela Thier Fellowship from LUMC, the Bas Mulder Award/Young lnvestigator Grant from Dutch Cancer Society (KWF), and the ERC Starting Grant from European Research Council.
Systematic identification of silencers in human cells.
Pang B., Snyder MP.
Nature Genetics. 2020, Feb24
Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin.
Pang B.*, Qiao X.*, Janssen L., Velds A., Groothuis T., Kerkhoven R., Nieuwland M., Ovaa H., Rottenberg S., van Tellingen O., Janssen J., Huijgens P., Zwart W. and Neefjes J.
Nature Communications. 2013;4:1908
Chemical profiling of the genome with anti-cancer drugs defines target specificities.
Pang B.*†, de Jong J.*, Qiao X.*, Wessels L.F.A.†, Neefjes J.†.
Nature Chemical Biology. 2015, 11, 472–480.